The toxic effects of TDF (tenofovir disoproxil fumarate) HIV anti-viral drugs – Truvada, Viread, Atripla, Complera, and Stribild – may lead to chronic kidney disease and other serious kidney complications.
A growing number of TDF HIV anti-viral drug lawsuits claim that Gilead downplayed these side effects and accuse the company of intentionally delaying a safer version of tenofovir to protect its bottom line.
The nationwide law firm of Bernstein Liebhard LLP is now investigating TDF HIV anti-viral drug lawsuits involving the following renal injuries:
To arrange for a free review of your case, please contact our office by calling (888) 994-5118.
TDF is indicated for the treatment and prevention of HIV, as well as the treatment of chronic hepatitis B.
Gilead received U.S. Food & Drug Administration (FDA) approval for Viread (tenofovir disoproxil fumarate of TDF) in 2001. Since then, the agency has approved the use of TDF in several combination drugs, including:
Since its introduction, TDF has been linked to more than 200,000 reports of chronic kidney disease and other kidney problems. A growing body of research also suggests that people taking TDF HIV anti-viral drugs may be more likely to suffer serious renal problems:
Recent TDF HIV anti-viral drug lawsuits filings have accused Gilead of downplaying the potential for Truvada, Viread, Atripla, Complera, and Stribild to cause chronic kidney disease and other serious renal problems.
Among other things, the complaints note that the FDA warned Gilead on two occasions regarding its marketing practices in regards to TDF medications:
The lawsuits also claim that Gilead delayed a safer version of tenofovir – tenofovir alafenamide or TAF – for more than a decade in order to maximize profits from its TDF medications.
“After learning that TAF had a higher absorption rate and largely avoided the bone and kidney toxicity associated with TDF, Gilead shelved its development of TAF and instead kept HIV infected patients and their doctors in the dark about the true risks associated with TDF, along with the solution to those risks, for over a decade,” the complaints assert. “In 2014, as Gilead’s patent on TDF approached its expiration and Gilead faced a sharp decrease in profits that would result from competition entering the market for TDF-containing drugs, Gilead decided to release the results of the TAF studies it began conducting in 2001.”
Gilead would obtain FDA approval for its first TAF drug in November 2015, a combination pill called Genvoy. It has since brought several other TAF medications to market, including Biktarvy and Descovy.
You may be eligible for financial compensation if you were diagnosed with chronic kidney disease or other kidney complications that may be related to treatment with Truvada, Viread, Atripla, Complera, and Stribild.
To learn more about filing a TDF HIV anti-viral drug lawsuit, contact our office for a free, no-obligation case review by calling (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.